Latest / The CEO Diary with Fexingo: Leadership Lessons, Executive Decisions, and Corner Office Stories
How Novo Nordisk Conquered the Obesity Market
In this episode of The CEO Diary, Lucas and Luna explore how Novo Nordisk transformed from a century-old Danish insulin maker into the world's most valuable pharmaceutical company, driven by its GLP-1 drugs Ozempic and Wegovy. They trace the strategic decisions by CEO Lars Fruergaard Jørgensen that turned a diabetes drug into a blockbuster weight-loss treatment, navigating supply shortages, pricing debates, and a massive manufacturing expansion. The hosts discuss how Novo Nordisk's 2025 market cap surpassed the entire Danish GDP, the company's $6.5 billion investment in new…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.